New antithrombotic agents

[1]  Eric J Topol,et al.  Platelet GPIIb-IIIa blockers , 1999, The Lancet.

[2]  T. Ortel,et al.  New treatment options for heparin-induced thrombocytopenia. , 1998, Seminars in hematology.

[3]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[4]  L. Deckelbaum,et al.  Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. , 1998, Journal of the American College of Cardiology.

[5]  J. Herbert,et al.  Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. , 1998, Blood.

[6]  M. Oz,et al.  Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. , 1998, The Journal of thoracic and cardiovascular surgery.

[7]  Gebhardt,et al.  International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina , 1998 .

[8]  P. Wille-Jørgensen,et al.  A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. , 1997, The New England journal of medicine.

[9]  R. Collins,et al.  Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO) , 1997 .

[10]  J. Herbert,et al.  Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. , 1997, The Journal of pharmacology and experimental therapeutics.

[11]  J. Weitz.  Low-molecular-weight heparins. , 1997, The New England journal of medicine.

[12]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[13]  Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II , 1997, The Lancet.

[14]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[15]  R. Kelley,et al.  A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. , 1997, Blood.

[16]  B. Coller.  Perspectives Series: Cell Adhesion in Vascular Biology Platelet Gpiib/iiia Antagonists: the First Anti-integrin Receptor Therapeutics , 2022 .

[17]  R. More,et al.  Antiplatelet rather than anticoagulant therapy with coronary stenting , 1997, The Lancet.

[18]  E. Antman.  Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.

[19]  A. Minford,et al.  Treatment of homozygous protein C deficiency with subcutaneous protein C concentrate , 1996, British journal of haematology.

[20]  J. Herbert,et al.  DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. , 1996, The Journal of pharmacology and experimental therapeutics.

[21]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[22]  M. Simoons.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.

[23]  B. Chaitman,et al.  Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. , 1995, The New England journal of medicine.

[24]  P. Serruys,et al.  A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. , 1995, The New England journal of medicine.

[25]  C. Esmon,et al.  An update on clinical and basic aspects of the protein C anticoagulant pathway. , 1995, Trends in cardiovascular medicine.

[26]  L. Wilkins.  Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. , 1994, Circulation.

[27]  R. Califf,et al.  Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. , 1994, Circulation.

[28]  E. Antman.  Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.

[29]  C. Patrono.  Aspirin as an antiplatelet drug. , 1994, The New England journal of medicine.

[30]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[31]  G. Vlasuk.  Structural and Functional Characterization of Tick Anticoagulant Peptide (TAP): A Potent and Selective Inhibitor of Blood Coagulation Factor Xa , 1993, Thrombosis and Haemostasis.

[32]  J. Miletich,et al.  Importance of factor Xa in determining the procoagulant activity of whole-blood clots. , 1993, The Journal of clinical investigation.

[33]  G. Broze.  The role of tissue factor pathway inhibitor in a revised coagulation cascade. , 1992, Seminars in hematology.

[34]  M. Ito,et al.  Ticlopidine: a new platelet aggregation inhibitor. , 1992, Clinical Pharmacist.

[35]  B. Furie,et al.  Molecular and cellular biology of blood coagulation. , 1992, The New England journal of medicine.

[36]  J. Hirsh.  Oral anticoagulant drugs. , 1991, The New England journal of medicine.

[37]  J. Hirsh.  Drug therapy : heparin , 1991 .

[38]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[39]  J. Maraganore,et al.  Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. , 1990, Biochemistry.

[40]  S. Yamamoto,et al.  Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. , 1990, Blood.

[41]  H. Adams,et al.  A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. , 1989, The New England journal of medicine.

[42]  V. Hachinski,et al.  THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE , 1989, The Lancet.

[43]  J. Hofsteenge,et al.  Kinetics of the inhibition of thrombin by hirudin. , 1986, Biochemistry.